Last reviewed · How we verify
OncoCare
At a glance
| Generic name | OncoCare |
|---|---|
| Sponsor | MyGenostics Inc., Beijing |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Feasibility Study of a Transition Pathway at Discharge From Full Hospitalization in Oncology
- Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study
- Colon Cancer Treatment Decisions and Recurrence Predicting (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OncoCare CI brief — competitive landscape report
- OncoCare updates RSS · CI watch RSS
- MyGenostics Inc., Beijing portfolio CI